For example, data from patients with diffuse large B-cell lymphoma (DLBCL) have shown that NLRP3 activation upregulated PD-L1 and reduced the proportion of cytotoxic T cells [59]. The gene discussed is NLRP3; the disease is diffuse large B-cell lymphoma.